证券代码：002773 证券简称：康弘药业 公告编号：2024-048 成都康弘药业集团股份有限公司 关于参加四川辖区2024年投资者网上集体接待日及半年度 报告业绩说明会活动的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流，成都康弘药业集团股份有限 公司（以下简称"公司"）将参加由四川省上市公司协会、上证所信 息网络有限公司、深圳市全景网络有限公司联合举办的"四川辖区 2024 年投资者网上集体接待日及半年度报告业绩说明会"活动，现将 相关事项公告如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演" （https://rs.p5w.net）参与本次互动交流，活动时间为 2024 年 9 月 12 日（周四）13:00-17:00。届时公司高管将在线就公司 2023 年 度及 2024 年半年度业绩、公司治理、发展战略、经营状况、融资计 划、股权激励和可持续发展等投资者关心的问题，与投资者进行沟通 与交流，欢迎广大投资者踊跃参与！ 特此公告。 成都康弘药业集团股份有限公司董事会 2024 年 9 月 9 日 ...

证券代码：002773 证券简称：康弘药业 公告编号：2024-047 成都康弘药业集团股份有限公司 关于2021年股票期权激励计划预留授予部分第二个行权期 自主行权的提示性公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 特别提示： 2、公司 2021 年股票期权激励计划符合预留授予部分第二个行 权期行权条件的 2 名激励对象在预留授予部分第二个行权期可行权 的股票期权数量共计 3.60 万份，行权价格为 14.44 元/股。 3、本次行权采用自主行权模式。 4、根据业务办理的实际情况，本次 2021 年股票期权激励计划预 留授予的第二个行权期实际可行权期限为 2024 年 9 月 5 日至 2025 年 7 月 10 日，激励对象可在行权期内的可行权日择机自主行权。 5、本次可行权股票期权若全部行权，公司股份仍具备上市条件。 成都康弘药业集团股份有限公司（以下简称"公司"）于 2024 年 8 月 22 日召开第八届董事会第八次会议，审议通过了《关于 2021 年 股票期权激励计划首次授予部分第三个行权期及预留授予部分第二 个行权期行权条件达成的议案》 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [2] Core Views - The company reported a revenue of 2.294 billion yuan for the first half of 2024, representing a year-on-year increase of 19.46%. The net profit attributable to the parent company was 0.692 billion yuan, up 31.77% year-on-year [4] - The company received market access approval for its product, Kangbai Xipu, in Myanmar, and is conducting clinical trials for a high-dose version aimed at treating diabetic macular edema [4] - The company has two gene therapy products approved for clinical trials in both China and the U.S., focusing on treating age-related macular degeneration [4] - The company has a rich pipeline of ophthalmic products and a long-term strategic layout, with projected net profits for 2024-2026 of 1.247 billion, 1.446 billion, and 1.606 billion yuan, respectively, corresponding to PE valuations of 13.7, 11.9, and 10.7 times [4] Financial Summary - In 2024E, the company is expected to achieve total revenue of 4.648 billion yuan, with a net profit of 1.247 billion yuan, reflecting a year-on-year growth rate of 17.4% for revenue and 19.4% for net profit [5] - The gross margin is projected to be 89.2% in 2024E, with a net profit margin of 26.8% [5] - The company’s total market capitalization is approximately 17.135 billion yuan, with a total asset value of 8.876 billion yuan [5] - The company’s earnings per share (EPS) is expected to increase from 1.14 yuan in 2023 to 1.36 yuan in 2024E [5]

| | | 成都康弘药业集团股份有限公司（以下简称"公司"）于 2024 年 8 月 22 日召开第八届董事会第八次会议和第八届监事会第八次会议， 审议通过了《关于注销 2021 年股票期权激励计划部分股票期权的议 案》。由于部分激励对象存在 2023 年度个人绩效考核未完全达标或未 达标、离职、首次授予部分第二个行权期满未行权及预留授予部分第 一个行权期满未行权等情形，董事会根据公司二〇二一年第一次临时 股东大会的授权，决定注销 277 名激励对象已获授但尚未行权的部分 或全部股票期权合计 250.9150 万份。具体内容详见公司于 2024 年 8 月 23 日刊登在巨潮资讯网（http://www.cninfo.com.cn）、《证券 时报》《中国证券报》《上海证券报》《证券日报》上的《关于注销 2021 年股票期权激励计划部分股票期权的公告》（公告编号：2024- 041）。 证券代码：002773 证券简称：康弘药业 公告编号：2024-045 成都康弘药业集团股份有限公司 关于2021年股票期权激励计划部分股票期权 注销完成的公告 期权事项符合《上市公司股权激励管理办法》及公司《2021 年股票期 ...

证券代码：002773 证券简称：康弘药业 公告编号：2024-044 成都康弘药业集团股份有限公司 关于使用自有资金购买理财产品的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 成都康弘药业集团股份有限公司（以下简称"康弘药业"或"公司"） 第八届董事会第六次会议和二〇二三年度股东大会审议通过了《关于使 用自有资金购买理财产品的议案》，同意公司及下属子公司使用部分闲 置自有资金在不超过人民币38亿元的额度内购买理财产品（包括结构性 存款），购买原则为安全性高、流动性好、由商业银行发行并提供保本 承诺的短期保本型理财产品（包括结构性存款），购买期限为自股东大 会审议通过之日起一年；在上述额度及期限内，资金可以滚动使用；董 事会授权公司总裁或财务负责人根据上述原则行使具体理财产品的购买 决策权，由财务部负责具体购买事宜，具体内容详见公司指定信息披露 媒体和巨潮资讯网（www.cninfo.com.cn）刊登于2024年4月25日《第八 届董事会第六次会议决议公告》（公告编号：2024-010）及2024年5月17 日《二〇二三年度股东大会决议公告》（公告编 ...

会计机构负责 | | | 井资产负债表 24年6月30日 | | | --- | --- | --- | --- | | 编制单位:成都康引 | | | 单位:人民币元 | | 功 | 附注 | 2024年6月30日 | 2024年1月1日 | | 流动资产: | | | | | 货币资金 | S 1 | 2, 999, 322, 489. 68 | 4, 702, 142, 704. 60 | | 结算备付金 | | | | | 拆出资金 | | | | | 交易性金融资产 | 七、2 | 2, 120, 000, 000. 00 | | | 衍生金融资产 | | | | | 应收票据 | 七、3 | | | | 应收账款 | 七、4 | 217, 366, 726. 06 | 160, 406, 614. 48 | | 应收款项融资 | | | | | 预付款项 | 七、6 | 25,533,757.43 | 10, 482, 586. 49 | | 应收保费 | | | | | 应收分保账款 | | | | | 应收分保合同准备金 | | | | | 其他应收款 | 七、5 | 12, 184, 809 ...

证券代码：002773 证券简称：康弘药业 公告编号：2024-040 成都康弘药业集团股份有限公司 关于2021年股票期权激励计划首次授予部分第三个行权期 及预留授予部分第二个行权期行权条件达成的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 特别提示： 1、公司 2021 年股票期权激励计划符合首次授予部分第三个行 权期行权条件的 252 名激励对象在首次授予部分第三个行权期可行 权的股票期权数量共计 234.9150 万份，行权价格为 21.65 元/股；符 合预留授予部分第二个行权期行权条件的 2 名激励对象在预留授予 部分第二个行权期可行权的股票期权数量共计 3.60 万份，行权价格 为 14.44 元/股。 2、本次行权采用自主行权模式。根据公司《2021 年股票期权激 励计划（草案）》，本次 2021 年股票期权激励计划首次授予股票期 权第三个行权期为自首次授予日起 36 个月后的首个交易日起至首次 授予日起 48 个月内的最后一个交易日当日止，预留授予股票期权的 第二个行权期为自预留授予日起 24 个月后的首个交易日起至预留授 予日起 3 ...

Financial Performance - The company's operating revenue for the first half of 2024 was ¥2,294,131,650.05, representing a 19.46% increase compared to ¥1,920,404,752.87 in the same period last year[11]. - Net profit attributable to shareholders of the listed company reached ¥692,220,039.94, up 31.77% from ¥525,339,192.02 year-on-year[11]. - The net profit after deducting non-recurring gains and losses was ¥678,370,200.35, reflecting a 33.10% increase from ¥509,652,451.63 in the previous year[11]. - The net cash flow from operating activities was ¥805,017,530.51, which is a 44.84% increase compared to ¥555,792,925.34 in the same period last year[11]. - Basic earnings per share increased to ¥0.75, up 31.58% from ¥0.57 in the previous year[11]. - Total assets at the end of the reporting period were ¥8,875,572,812.88, a 4.06% increase from ¥8,529,680,910.70 at the end of the previous year[11]. - Net assets attributable to shareholders of the listed company were ¥8,153,759,334.68, reflecting a 4.48% increase from ¥7,804,029,406.63 at the end of the previous year[11]. - The company achieved operating revenue of CNY 2,294,131,650.05, representing a year-on-year growth of 19.46%[25]. - Net profit attributable to shareholders reached CNY 69,222,000, marking a year-on-year increase of 31.77%[23]. - Research and development investment amounted to CNY 195,209,786.20, reflecting a 6.90% increase compared to the previous year[25]. Strategic Focus and Product Development - The main business focus remains on the R&D, manufacturing, and sales of pharmaceuticals and medical devices, with no significant changes in the first half of 2024[15]. - The company emphasizes innovation in biopharmaceutical technology and green synthesis of chemical raw materials as key competitive advantages[15]. - The product pipeline includes various medications for conditions such as diabetes, depression, and eye diseases, with several products covered by national health insurance[16][17]. - The company aims to enhance its market presence through continuous product innovation and strategic collaborations[15]. - The overall strategy focuses on high-quality and sustainable growth in the pharmaceutical industry[15]. - The company has developed a product portfolio focused on chronic diseases such as hypertension and diabetes, with a strong emphasis on innovative treatments for common diseases in respiratory and digestive fields[19]. - The company is advancing several key projects in clinical trials, including KH631 and KH658 for age-related macular degeneration, and KH110 for Alzheimer's disease, with KH110 currently in Phase III trials[20]. - The company has established a comprehensive R&D system, integrating various research institutes and focusing on key therapeutic areas such as ophthalmology, neurology, and oncology[19]. - The company is actively expanding its international presence, with multiple first-class new drugs and international patents, aiming to explore global markets[21]. - The company has two gene therapy projects approved for clinical trials in both China and the U.S., highlighting its innovation in biopharmaceuticals[21]. Financial Management and Investment - Investment income from financial products reached ¥19,373,394.19, indicating effective cash management strategies[14]. - The company reported a non-operating loss of ¥213,897.27 from the disposal of non-current assets[13]. - Government subsidies recognized in the current period amounted to ¥20,475,317.28, contributing positively to the financial results[13]. - The company incurred a loss of ¥969,600.00 related to cash-settled share-based payments[13]. - The company’s cash and cash equivalents decreased by 179.50% to CNY -1,720,992,926.66, primarily due to increased investments in financial products[25]. - The total amount of raised funds used in the reporting period was ¥756.77 million, with a cumulative usage of ¥210.58 million[31]. - The solid oral dosage form project has achieved an investment progress of 92.24% with a cumulative investment of ¥23,181.67 million[32]. Environmental Compliance and Sustainability - The company is classified as a key pollutant discharge unit and adheres to various environmental protection laws and standards[59]. - Chengdu Kanghong Pharmaceutical Group reported significant progress in environmental compliance with multiple projects receiving environmental impact assessments and completion approvals, including the solid oral dosage technology transformation project and the innovative biological new drug laboratory project[60][61][62]. - The company has implemented a comprehensive environmental emergency response plan, demonstrating its commitment to environmental safety and compliance[61]. - The company is committed to sustainable practices, as shown by its adherence to various environmental regulations and standards across its projects[60][61]. - The company has established a comprehensive environmental monitoring plan, including online monitoring systems for key pollutants such as COD and ammonia nitrogen[87]. - The company is focused on maintaining sustainable practices, as evidenced by the consistent compliance with environmental standards across all monitored parameters[74]. Corporate Governance and Social Responsibility - The company emphasizes compliance with laws and regulations to protect shareholder and creditor rights, ensuring value creation for shareholders[97]. - Chengdu Kanghong Pharmaceutical actively participates in social welfare and charity initiatives, promoting public health and positive energy in the pharmaceutical sector[96]. - The company has been recognized as a leading enterprise in social responsibility, receiving multiple awards in the first half of 2024[105]. - The company donated over 8.72 million yuan in social welfare contributions in the first half of 2024, with cumulative donations exceeding 614 million yuan[104]. - The company established 6 traditional Chinese medicine planting bases across four provinces, covering over 4,000 acres, providing employment for over 450 local farmers and generating over 2.4 million yuan in income for them[106]. Shareholder Information and Stock Options - The total number of shares increased from 919,463,954 to 919,756,504 due to the exercise of stock options, resulting in an increase of 292,550 shares[128]. - The largest shareholder, Chengdu Kanghong Technology Industry Group Co., Ltd., holds 31.75% of the shares, totaling 292,014,900 shares[131]. - The stock options exercise was approved by the board on August 25, 2023, and has been registered with the Shenzhen Securities Registration and Clearing Company[128]. - The company has not implemented any share buyback during the reporting period[129]. - The report indicates that the stock option exercise diluted the earnings per share and net asset value per share metrics[128]. Market Expansion and Future Outlook - The company plans to launch three new products in the next quarter, targeting a market expansion of 10% in the oncology segment[89]. - The company aims for a revenue growth target of 12% for the full year 2024, with a projected revenue of CNY 3.2 billion[89]. - Market expansion efforts include entering two new provinces, which are expected to contribute an additional CNY 100 million in revenue[89]. - The company is exploring potential acquisitions to enhance its product portfolio, with a budget of CNY 500 million allocated for this purpose[89]. - Future guidance estimates a revenue growth of 18% for the full year 2024, driven by new product launches and market expansion[90].